HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
About this item
Full title
Author / Creator
Publisher
Beijing: Higher Education Press
Journal title
Language
English
Formats
Publication information
Publisher
Beijing: Higher Education Press
Subjects
More information
Scope and Contents
Contents
Immunotherapy has been applied successfully to treat B-cell lymphomas in preclinical models or clinical settings. However, immunotherapy resistance is a major challenge for B-cell lymphoma treatment. To overcome this issue, combinatorial therapeutic strategies have been pursued to achieve a better efficacy for treating B-cell lymphomas. One of such...
Alternative Titles
Full title
HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_d9e84d707dd3487cac150e395a2a17fd
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d9e84d707dd3487cac150e395a2a17fd
Other Identifiers
ISSN
1674-800X,1674-8018
E-ISSN
1674-8018
DOI
10.1007/s13238-020-00694-x
